May. 13 at 10:00 PM
$CATX And as you saw in those images, and we and we do it first in animals, and then we go to the humans after that. So it's a, it's a. Methodical process that leads us down the path. And we won't spend investor dollars on the big, expensive trials until all those boxes are checked. And the beauty of it is, is that a lot of that front end work goes in. And that's very different than Non-radio targeted compounds. Your traditional targeted oncology. Because you can theoretically think that your drug is only going to go to tumor, but you don't really know what that side effect profile is going to be until you test it in patients. We have a really strong. Conviction of our drugs before they even go into the first clinical trial, that they're going to be safer than they would have otherwise be have been because we've integrated that into our theranostics element. Plus. We have the proprietary Chelator to add extra insurance to keep the compound safe. Yeah.
